Novel Steroid Sparing Strategies for the Treatment of Uveitis and Prevention of Corneal Transplant Rejection to be Subject of International Symposium Sponsored by Lux Biosciences

JERSEY CITY, NJ (August 30, 2007): Novel steroid sparing strategies for the treatment of uveitis and the prevention of
corneal transplant rejection will be the subject of a Symposium “Steroid Sparing Approaches in Immunomodulation” sponsored
by Lux Biosciences at the 9^th International Congress of the International Ocular Inflammatory Society in Paris, France on
Monday, September 17.

The Symposium, which features presentations by several notable international ophthalmic experts, will include discussions of two ongoing worldwide Phase 3 clinical programs sponsored by Lux Biosciences. LUMINATE (Lux Uveitis Multi-Center Investigation of a New Approach to Treatment) is a 500-patient clinical investigation of LX211, a next-generation calcineurin inhibitor, which consists of three controlled, multi-center, double-masked, placebo-controlled studies for the uveitis indication. LUCIDA (Lux Corneal Transplant Implant Development and Advancement of Therapy) is a clinical investigation of LX201, a novel treatment preventing a transplanted cornea from being rejected by the body’s immune system. The LUCIDA program consists of two multi-center, randomised placebo-controlled studies that will enroll over 400 patients worldwide. In addition to presentations of the trial designs for each of these programs, the Symposium will include discussions of the risk versus benefits of uveitis treatment and emerging outcome parameters in uveitis.

The Symposium will be held from 16:00 – 17:30 in Room Derain, at the Meridien Etoile Hotel in Paris. For more information on the Symposium, please visit www.iois-paris-2007.com

About Lux Biosciences

Lux Biosciences is a privately held biotechnology company dedicated to the identification, optimization, development and commercialization of products for the treatment of ophthalmic diseases. The company's business strategy is characterized by:

A focus on compounds already marketed or with clinical proof-of-concept in non-ophthalmic indications that Lux Biosciences will develop as unique, targeted therapies for corresponding ophthalmic diseases, with potentially greater efficacy and safety than existing treatments.
A clinical-stage portfolio of projects including: i) LX211, a next-generation calcineurin inhibitor that has potential in several ophthalmic diseases and, as such, represents a pipeline of product opportunities; and ii) LX201, a silicone matrix ocular (episcleral) implant that steadily releases therapeutic doses of cyclosporine A locally to the eye. Both the LUMINATE pivotal clinical program for LX211 for the treatment of uveitis, as well as the LUCIDA pivotal clinical program with LX201 for the prevention of corneal transplant rejection were initiated in early 2007.
Proprietary product-enabling bio-erodible polymer technologies that facilitate targeted and sustained delivery of molecules to the eye.

For more information on Lux Biosciences, please visit the company’s website at www.luxbio.com.

###

CONTACTS:

Lux Biosciences, Inc.
Ulrich Grau, Ph.D.
+1 201 946 0221
ulrich.grau@luxbio.com

Kureczka/Martin Associates (media)
Joan Kureczka

+1 415 821 2413

Jkureczka@comcast.net